Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

66.81
+0.23000.35%
Post-market: 66.920.1100+0.16%18:45 EDT
Volume:12.68M
Turnover:846.66M
Market Cap:136.01B
PE:14.71
High:67.20
Open:66.25
Low:65.91
Close:66.58
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:1.95
T/O Rate:0.62%
Dividend:2.51
Dividend Rate:3.76%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:6.09
PE(LYR):19.31

Loading ...

Bristol Myers CEO Says Potential Interim Analysis for Adept 1 Trial Could Come Later This Year

THOMSON REUTERS
·
Jul 30

Bristol Myers Q2 Adjusted EPS $2.04 Versus IBES Estimate $1.59

Reuters
·
Jul 30

Bristol Myers Q2 GAAP EPS Rises to 1.62; Revenue Increases 5.7% to 13 Billion

Reuters
·
Jul 30

Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly Beat

Dow Jones
·
Jul 30

Bristol Myers Squibb Posts Fiscal Q2 2026 Earnings Release, Investor Presentation Online

Reuters
·
Jul 30

Earnings Flash (BMY) Bristol-Myers Squibb Posts Q2 Revenue $12.97B, vs. FactSet Est of $11.74B

MT Newswires Live
·
Jul 30

Bristol-Myers Squibb Q2 Adj. EPS $2.04 Beats $1.59 Estimate, Sales $12.973B Beat $11.745B Estimate

Benzinga Earnings
·
Jul 30

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

THOMSON REUTERS
·
Jul 30

Bristol Myers Q2 REV $12.97 Bln vs Ibes Estimate $11.75 Bln

THOMSON REUTERS
·
Jul 30

Bristol Myers Outlook FY Eliquis REV Growth 20%-25% vs Prior Forecast of 10%-15%

THOMSON REUTERS
·
Jul 30

Bristol Myers Raises 2026 Forecast as Eliquis, Newer Medicines Power Results

Reuters
·
Jul 30

Cytokinetics Wins UK Approval, NICE Backing for Heart Disease Drug

Reuters
·
Jul 30

U.S. Earnings Preview: Before Market Open July 30

Dow Jones
·
Jul 30

How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings

Benzinga Earnings
·
Jul 29

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff

Benzinga
·
Jul 29

Movement Alert|Bristol-Myers Squibb Rises 3.05% in Regular Trading, AI Drug Discovery Partnerships and Upcoming Earnings Boost Sentiment

Market Focus
·
Jul 28

Bristol-Myers Squibb: Market Perform Rating Reiterated with Unchanged $60 Price Target Amid Steady but Measured Growth Outlook

TIPRANKS
·
Jul 28

Simris Group Names Dr. Tiffany J. Vora Strategic Advisor

Reuters
·
Jul 28

MapLight's Schizophrenia Drug Fails Once-daily Test, Shares Plunge

Reuters
·
Jul 27

Legend Biotech Names Alan Bash Interim CEO After Ying Huang Resigns

Reuters
·
Jul 27